Corcept Therapeutics Incorporated (CORT) — AI News Sentiment & Analysis

The primary catalyst is the strong Q2 2026 financial performance, driven by existing and new product demand (Korlym and Lifyorli), coupled with the significantly raised 2026 revenue guidance. This signals sustained operational momentum and de-risks future revenue streams. (Timing: Over the next 6-12 months, as the company continues to execute on its raised guidance and Lifyorli gains further market traction.)

FDA resubmission of NDA for relacorilant, triggering a new six-month review period. (Timing: Within 6 months)

Presentation of new clinical data at the American Diabetes Association's Scientific Sessions showing improved outcomes for Korlym in Type 2 Diabetes patients treated with GLP-1s. This significantly expands the potential market for Korlym. (Timing: Immediate)

The presentation of new, compelling overall survival data from the pivotal Phase 3 ROSELLA trial for Lifyorli at ASCO 2026 will drive increased adoption and market penetration for the recently FDA-approved drug. (Timing: Immediate impact from presentation, with sustained adoption over the next 12-24 months as physicians incorporate the new data into practice.)

Positive two-year overall survival data from the Phase 2 DAZALS study of dazucorilant in Amyotrophic Lateral Sclerosis (ALS), showing an 87% reduction in risk of death. (Timing: Initiation of pivotal Phase 3 study later this year; future regulatory approvals will depend on Phase 3 outcomes.)

The formal filing of a securities class action lawsuit against Corcept Therapeutics, alleging the company misled investors about critical FDA warnings for its drug relacorilant. (Timing: The lawsuit's legal proceedings are ongoing, with a lead plaintiff deadline of April 21, 2026. This indicates a prolonged period of legal uncertainty, potentially extending over several months to years.)

The official filing of a securities class action lawsuit, potentially leading to further negative developments or financial penalties for the company. (Timing: Ongoing legal proceedings (likely several months to years))

The primary catalysts are the strong 2026 revenue guidance ($900M - $1,000M), the PDUFA date of July 11, 2026, for relacorilant in platinum-resistant ovarian cancer, and positive overall survival results from the ROSELLA study for the same indication. Several other clinical trial readouts are expected by the end of 2026 and into 2027. (Timing: Medium-term (July 2026 for PDUFA, ongoing into 2027 for other clinical trial readouts and full realization of 2026 guidance).)